lifestyle.d-h.st

Author: PineTree Therapeutics

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

April 29, 2026
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology

October 30, 2025